Lymphoma Clinical Trials in Florida

Showing 241-260 of 307 trials

A Safety Study of SGN-CD19A for B-Cell Lymphoma

NCT01786135

This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)

Burkitt LymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse+2 more

Seagen Inc.64 participantsStarted Feb 2013

Birmingham, Alabama, United States • Duarte, California, United States • Stanford, California, United States +3 more locations

COMPLETEDPhase 349 miles

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

NCT00053053

RATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two nutritional supplements in preventing loss of appetite, weight loss, and fatigue in patients who have stage III or stage IV solid tumors.

CachexiaLymphomaLymphoproliferative Disorder+1 more

Radiation Therapy Oncology Group472 participantsStarted Dec 2002

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Mobile, Alabama, United States +247 more locations

PreviousPage 13 of 16Next

A Safety Study of SGN-CD19A for B-Cell Lymphoma

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

Lymphoma Trials in Other Cities

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Other Conditions in Florida